MarketCap
Facebook
X
TelegramQuarterly report 2024-Q2
added 08-12-2024
Agile Therapeutics Total Assets 2011-2026 | AGRX
Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.Main categories of assets
Current assets (used within one year):
- Cash and cash equivalents
- Accounts receivable (amounts owed by customers)
- Inventory of goods, raw materials, and supplies
- Short-term investments
- Fixed assets (buildings, machinery, equipment)
- Intangible assets (brands, patents, software)
- Long-term investments
- Goodwill (reputational value from mergers)
Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.
Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.
Annual Total Assets Agile Therapeutics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 10.3 M | 14.2 M | 39.3 M | 73.1 M | 49.5 M | 22.4 M | 50.6 M | 63.9 M | 50.7 M | 54.8 M | 14.4 M | 27.5 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 73.1 M | 10.3 M | 39.2 M |
Quarterly Total Assets Agile Therapeutics
| 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 15 M | 12.6 M | 10.3 M | 10.9 M | 12.6 M | 13.7 M | 14.2 M | 18.5 M | 32.8 M | 29.3 M | 39.3 M | 36.7 M | 52.3 M | 59.5 M | 73.1 M | 73.1 M | 73.1 M | 73.1 M | 49.5 M | 49.5 M | 49.5 M | 49.5 M | 22.4 M | 22.4 M | 22.4 M | 22.4 M | 50.6 M | 50.6 M | 50.6 M | 50.6 M | 63.9 M | 63.9 M | 63.9 M | 63.9 M | 50.4 M | 50.4 M | 50.4 M | 50.4 M | 54.8 M | 54.8 M | 54.8 M | 54.8 M | 14.4 M | 14.4 M | 14.4 M | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 73.1 M | 10.3 M | 41.3 M |
Total Assets of other stocks in the Drug manufacturers industry
| Issuer | Total Assets | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Alimera Sciences
ALIM
|
154 M | - | - | $ 142 M |  USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
10.9 M | - | 0.86 % | $ 117 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
431 M | - | - | $ 754 M | USA |
 |
Cronos Group
CRON
|
1.93 B | $ 2.66 | -0.56 % | $ 1.4 B |  Canada |
 |
Canopy Growth Corporation
CGC
|
918 M | $ 1.28 | 7.8 % | $ 138 M | Canada |
 |
AcelRx Pharmaceuticals
ACRX
|
18.2 M | - | 7.5 % | $ 6.35 M | USA |
 |
Catalent
CTLT
|
9.75 B | - | - | $ 11.5 B | USA |
 |
DURECT Corporation
DRRX
|
45.2 M | - | - | $ 50.1 M | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
1.46 B | - | -0.1 % | $ 2.03 B |  Schweden |
 |
Eagle Pharmaceuticals
EGRX
|
406 M | - | -39.89 % | $ 27.7 M | USA |
 |
HEXO Corp.
HEXO
|
681 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Endo International plc
ENDP
|
5.14 B | - | - | $ 28.9 M |  Irlanda |
 |
Evoke Pharma
EVOK
|
7.07 M | - | - | $ 36.6 M | USA |
 |
Emergent BioSolutions
EBS
|
1.82 B | $ 13.4 | -3.67 % | $ 686 M | USA |
 |
Athenex
ATNX
|
204 M | - | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
164 M | $ 21.48 | -0.09 % | $ 2.04 B |  France |
 |
Rockwell Medical
RMTI
|
52.2 M | $ 1.0 | 4.65 % | $ 23.3 M | USA |
 |
Sundial Growers
SNDL
|
1.35 B | $ 1.65 | -0.3 % | $ 3.37 M | Canada |
 |
Sonoma Pharmaceuticals
SNOA
|
13.7 M | $ 3.82 | 1.33 % | $ 4.74 M | USA |
 |
Evolus
EOLS
|
233 M | $ 5.72 | 0.97 % | $ 355 M | USA |
 |
Harrow Health
HROW
|
312 M | $ 50.59 | -0.81 % | $ 1.65 B | USA |
 |
China Pharma Holdings
CPHI
|
14.9 M | $ 1.39 | 2.21 % | $ 24.3 M |  China |
 |
Jupiter Wellness
JUPW
|
7.34 M | - | - | $ 33.6 M | USA |
 |
OrganiGram Holdings
OGI
|
408 M | $ 1.74 | 3.57 % | $ 402 M | Canada |
 |
Bausch Health Companies
BHC
|
27.4 B | $ 7.81 | -1.2 % | $ 2.85 B | Canada |
 |
Pacira BioSciences
PCRX
|
1.55 B | $ 26.09 | 0.35 % | $ 1.21 B | USA |
 |
Lannett Company
LCI
|
484 M | - | 1.15 % | $ 7.11 M | USA |
 |
Veru
VERU
|
60.4 M | $ 2.32 | -2.11 % | $ 313 M | USA |
 |
Cumberland Pharmaceuticals
CPIX
|
75.6 M | $ 4.78 | -7.96 % | $ 67.2 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
223 M | - | - | $ 193 M | Canada |
 |
Organogenesis Holdings
ORGO
|
498 M | $ 4.25 | -1.28 % | $ 560 M | USA |
 |
Aurora Cannabis
ACB
|
853 M | $ 4.25 | 0.12 % | $ 86.3 M | Canada |
 |
PetIQ
PETQ
|
868 M | - | 1.64 % | $ 400 M | USA |
 |
Recro Pharma
REPH
|
153 M | - | -4.76 % | $ 65.3 M | USA |
 |
cbdMD
YCBD
|
10.6 M | $ 1.1 | - | $ 4.74 M | USA |
 |
Perrigo Company plc
PRGO
|
9.65 B | $ 14.84 | 1.64 % | $ 2.04 B | USA |
 |
ProPhase Labs
PRPH
|
87.6 M | - | - | $ 5.07 M | USA |
 |
Radius Health
RDUS
|
182 M | - | - | $ 1.42 B | USA |
 |
Relmada Therapeutics
RLMD
|
97.6 M | $ 4.4 | 1.85 % | $ 132 M | USA |
 |
OptiNose
OPTN
|
108 M | - | - | $ 1.08 B | USA |
 |
Assertio Holdings
ASRT
|
286 M | $ 9.4 | -0.32 % | $ 668 M | USA |
 |
PLx Pharma
PLXP
|
76.6 M | - | -27.8 % | $ 2.56 M | USA |
 |
Solid Biosciences
SLDB
|
189 M | $ 5.32 | -5.17 % | $ 217 M | USA |
 |
SCYNEXIS
SCYX
|
128 M | $ 0.67 | 3.96 % | $ 32.1 M | USA |
 |
Tricida
TCDA
|
169 M | - | - | $ 3.25 M | USA |
 |
Tilray
TLRY
|
4.31 B | $ 9.13 | 1.57 % | $ 5.64 B | Canada |
 |
TherapeuticsMD
TXMD
|
43.3 M | $ 2.01 | -1.62 % | $ 21 M | USA |
 |
Viatris
VTRS
|
50 B | $ 12.61 | 1.16 % | $ 15.3 B | USA |
 |
Zomedica Corp.
ZOM
|
253 M | - | -0.21 % | $ 98 M | USA |